NCT05110742View on ClinicalTrials.gov

Phase I/II Study of CD5 CAR Engineered IL15-Transduced Cord Blood-Derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapsed/Refractory Hematological Malignances

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

48

Participants

Timeline

Start Date

April 22, 2024

Primary Completion Date

December 30, 2027

Study Completion Date

December 30, 2027

Conditions
Hematological Malignancy
Interventions
DRUG

Fludarabine Phosphate

Given by IV

DRUG

Cyclophosphamide

Given by IV

DRUG

CAR.5/IL15-transduced CB-NK cells

Given by IV

Trial Locations (1)

77030

RECRUITING

M D Anderson Cancer Center, Houston

All Listed Sponsors
lead

M.D. Anderson Cancer Center

OTHER